Andexxa (Ondexxya) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Andexxa (Ondexxya) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to the rising incidence of bleeding complications, an increase in the number of patients undergoing anticoagulant therapies, a growing geriatric population, higher healthcare expenditures, and an increase in stroke and cardiovascular diseases.

The projected growth during the forecast period is driven by the growing demand for minimally invasive surgeries, a rising number of patients with hemophilia, the increasing establishment of retail pharmacies, a surge in clinical trials, and mounting pressure on healthcare systems. Key trends in the forecast period include technological advancements, the rise of personalized medicine, the integration of digital health tools, improvements in genetic testing, and the development of personalized treatment plans.

The growing prevalence of bleeding disorders is expected to drive the expansion of the andexxa (ondexxya) market in the coming years. Bleeding disorders are a group of conditions that affect the blood's ability to clot properly, leading to excessive or prolonged bleeding. The rise in these disorders can be attributed to improved diagnosis, increased awareness, genetic factors, and an aging population, all of which contribute to greater recognition and detection of such conditions. Andexxa (Ondexxya) plays a critical role in managing bleeding disorders by rapidly reversing the anticoagulant effects of factor Xa inhibitors, helping prevent life-threatening bleeding in emergency situations. For example, a report from the World Federation of Hemophilia published in October 2023 revealed that in 2022, 427,685 individuals worldwide were diagnosed with bleeding disorders, including 257,146 cases of hemophilia, 100,505 cases of von Willebrand disease, and 70,034 cases of other bleeding disorders. As a result, the rising prevalence of bleeding disorders is driving demand for andexxa (ondexxya).

The increasing geriatric population is also expected to boost the growth of the andexxa (ondexxya) market. The geriatric population, defined as individuals aged 65 and older, often faces age-related health challenges, including chronic diseases, cognitive decline, and mobility issues. This population is growing globally due to increased life expectancy and advancements in healthcare. Andexxa (Ondexxya) is particularly beneficial for older adults, as it helps reverse bleeding caused by blood thinners, which are commonly used by the elderly, especially those with conditions such as atrial fibrillation. According to a report by the World Health Organization (WHO) published in October 2022, one in six people worldwide is expected to be 60 or older by 2030, and by 2050, there will be 2.1 billion people aged 60 or older. This growing geriatric population is driving the demand for andexxa (ondexxya).

An important trend in the andexxa (ondexxya) market is the focus on developing innovative reversal agents to neutralize the anticoagulant effects of medications, especially for patients experiencing severe bleeding. Reversal agents are designed to counteract the effects of specific drugs, restoring normal physiological function. For example, in March 2022, AstraZeneca announced that Japan had officially approved Ondexxya for treating acute massive bleeding in certain patients. Ondexxya, a specially designed protein to reduce excessive bleeding, became the first medication in Japan to receive full regulatory approval for use with all three currently available factor Xa (FXa) inhibitors. This approval allows AstraZeneca to provide Ondexxya to patients with life-threatening or uncontrolled bleeding while on FXa inhibitors, addressing a previously unmet need for an approved reversal agent.

The key company operating in the andexxa (ondexxya) market is AstraZeneca Plc.

North America was the largest region in the andexxa (ondexxya) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in andexxa (ondexxya) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the andexxa (ondexxya) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Andexxa (Ondexxya) is a reversal agent designed to counteract the anticoagulant effects of certain blood thinners, particularly Factor Xa inhibitors such as rivaroxaban (Xarelto) and apixaban (Eliquis). It is used in situations involving life-threatening or uncontrolled bleeding or when immediate reversal of anticoagulation is needed.

The primary indications for andexxa (Ondexxya) include reversing bleeding caused by Factor Xa inhibitors, managing acute major bleeding events, and supporting emergency surgeries or procedures. Factor Xa inhibitors are anticoagulants that prevent blood clotting, but in cases of severe bleeding, their effects may need to be reversed. The medication is distributed through various channels such as hospital pharmacies and specialty pharmacies, and is used by adults, geriatric patients, and pediatric patients.

The andexxa (ondexxya) market research report is one of a series of new reports that provides andexxa (ondexxya) market statistics, including andexxa (ondexxya) industry global market size, regional shares, competitors with a andexxa (ondexxya) market share, detailed andexxa (ondexxya) market segments, market trends and opportunities, and any further data you may need to thrive in the andexxa (ondexxya) industry. This andexxa (ondexxya) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The andexxa (ondexxya) market consists of sales of anticoagulant reversal agents, factor xa inhibitors, hemostatic agents and blood clotting factor concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.